Global Companion Diagnostic Technologies Market (Indication
and Geography) - Size, Share, Global Trends, Company
Profiles,...
Companion diagnostics are a form of in-vitro diagnostics which provide data about the
therapeutic reactions of patients fo...
America and Europe together represented in excess of 82% in the worldwide CD market in 2013
and they would keep on being t...
KEY BENEFITS
 In-depth analysis of the companion diagnostic market by technology and indications
give a clear idea of the...
Table of Content
CHAPTER 1. INTRODUCTION
1.1 Reportdescription
1.2 Keymarketsegments
1.3 Researchmethodology
1.3.1 Seconda...
3.12.1.1 Economicand scientificobstacles
3.12.2 Opportunities
3.12.2.1 Opportunitiesintreatmentof neurodegenerative diseas...
5.3.6 Others
5.3.6.1 Othersmolecularcompaniondiagnosticsmarketbygeography
CHAPTER 6. GLOBAL COMPANION DIAGNOSTICS BY GEOGR...
7.5.4 StrategiesanddevelopmentApproval
7.5.5 SWOT Analysisof BioMerieux,
7.6 VentanaMedical Systems
7.6.1 CompanyProfile
7...
TABLE 12 COMPANION DIAGNOSTICSCNSMARKETBY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 13 COMPANION DIAGNOSTICSVIROLOGYMARKETBY G...
FIG.13 FINANCIALREVENUEOF DAKO,BY GEOGRAPHY
FIG.14 SWOT ANALYSISOFROCHE
FIG.15 REVENUE BY BUSINESSSEGMENTS
FIG.16 REVENUE ...
Upcoming SlideShare
Loading in...5
×

Global Companion Diagnostic Technologies Market (Indication and Geography) – Reports and Intelligence

311

Published on

Get full details of report at: http://www.reportsandintelligence.com/companion-diagnostic-technologies-market

Companion diagnostics are a form of in-vitro diagnostics which provide data about the therapeutic reactions of patients for a particular treatment. Companion diagnostics market is still developing, and it is expected to reach a market value of $3.5 billion by 2020 from a market value of $1.1 billion in the year 2013, registering a CAGR of 20% during 2014-2020. The global companion diagnostic market is divided on the basis of technology, geography and indication (North America, Europe, Asia Pacific and LAMEA). Geographically, LAMEA is growing rapidly. Factors that are contributing towards the growth of market are invention of biomarkers and co-development of drug and corresponding diagnostic. However, high cost of drug development would deter the market growth. Opportunities for the market would be in the development of companion diagnostics for hereditary conditions numerous central nervous system conditions.

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
311
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Global Companion Diagnostic Technologies Market (Indication and Geography) – Reports and Intelligence

  1. 1. Global Companion Diagnostic Technologies Market (Indication and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020 Published: June 2014 Pages: 107 Contact Us: +1 (617) 674-4143 Toll Free: +1 (855) 711-1555 Mail us: sales@reportsandintelligence.com Detailed report at: http://www.reportsandintelligence.com/companion-diagnostic- technologies-market
  2. 2. Companion diagnostics are a form of in-vitro diagnostics which provide data about the therapeutic reactions of patients for a particular treatment. Companion diagnostics market is still developing, and it is expected to reach a market value of $3.5 billion by 2020 from a market value of $1.1 billion in the year 2013, registering a CAGR of 20% during 2014-2020. The global companion diagnostic market is divided on the basis of technology, geography and indication (North America, Europe, Asia Pacific and LAMEA). Geographically, LAMEA is growing rapidly. Factors that are contributing towards the growth of market are invention of biomarkers and co- development of drug and corresponding diagnostic. However, high cost of drug development would deter the market growth. Opportunities for the market would be in the development of companion diagnostics for hereditary conditions numerous central nervous system conditions. Companion Diagnostics Indication Market Analysis Companion diagnostics is divided based on its utilization for indication, for example, oncology, cardiovascular conditions, focal sensory system evidences, irritation and virology. Oncology is the maximum revenue generating segment, as most of the CD technology has been developed to invent oncology biomarkers. Increasing research and development of targeted drugs is the main driving factor for this market. Companion Diagnostics Technology Market Analysis The report segments the companion diagnostics technology market on the basis of Immunohistochemistry and Molecular diagnostics. Atomic diagnostics would be the quickest developing and the maximum income generator, basically because of the utilization of procedures, for example, constant PCR, In Situ Hybridization and cutting edge sequencing. Different components helping the development are mechanical progressions in atomic diagnostics, which has brought about expanded precision and exactness and likewise decreased expense of testing through these methods. Companion Diagnostics Geography Market Analysis Companion Diagnostics market has been sectioned geographically into North America, Europe, Asia Pacific and LAMEA. North America has the significant piece of the pie of 43.97%, followed by Europe, which represented something like 38% of the general CD market in 2013. North
  3. 3. America and Europe together represented in excess of 82% in the worldwide CD market in 2013 and they would keep on being the significant markets until 2020.. Competitive Analysis A detailed research of key players has demonstrated that most of the companies in this business sector are concentrating on coordinated efforts with drug organizations. The top players included in the report are Dako (Agilent Technologies), Qiagen, Roche, Abbott Laboratories, Inc., Ventana Medical Systems, biomerieux, Myriad Genetics, Inc., Resonance Health Ltd., Leica Microsystems, and Life Technologies. High Level Analysis The report is concentrating on the patterns in diagnosis and technology of various indications, which are driving the development of the companion diagnostics market. Research of the business is focused around others five force model that shows the negotiating power of the suppliers is high, as the items delivered are very distinguished. The risk of new entrants is low as noteworthy innovative work is needed for creating diagnostic tests. Further, the cash flow required is also high. These components make it difficult for new organizations to enter the business. The risk of substitutes is low in this business sector as companion diagnostics are created for particular biomarkers and the products are highly distinguished. Since it is an emerging market with few companies, the completion is not high. Government regulations are favoring utilization of companion diagnostics for the deciding a specific treatment. Organizations are concentrating on joint efforts with pharmaceutical organizations as a key procedure to further bolster the market growth. Reason for doing the study Companion diagnostics are a critical part of the personalized treatment approach and are fundamental to identify therapeutic response to a specific medication. Rising cases of diseases and healthcare awareness would increase the market scope.
  4. 4. KEY BENEFITS  In-depth analysis of the companion diagnostic market by technology and indications give a clear idea of the scope of this market  Analysis of the market by geography would help in making region specific plans  Estimations for period of 2013 to 2020 have been given, taking into consideration the current market scenario and future trends, which would give a clearer picture of the potential of the market  Porter’s five force model and SWOT analysis would help in a deeper understanding of the market and help in making strategic decisions  Top factors impacting the market would help in making decisions for business development KEY DELIVERABLES MARKET BY INDICATIONS  Oncology  Cardiovascular  Central Nervous System  Auto immune & Inflammation  Virology  Others MARKET BY TECHNOLOGY  Immunohistochemistry  Molecular diagnostics o In situ Hybridization  FISH  CISH o Real time PCR o Gene Sequencing MARKET BY GEOGRAPHY  North America  Europe  Asia Pacific  LAMEA
  5. 5. Table of Content CHAPTER 1. INTRODUCTION 1.1 Reportdescription 1.2 Keymarketsegments 1.3 Researchmethodology 1.3.1 Secondaryresearch 1.3.2 Primaryresearch 1.3.3 Analysttoolsandmodels CHAPTER 2. EXECUTIVE SUMMARY CHAPTER 3. MARKETOVERVIEW 3.1 MarketDefinitionand Scope 3.2 CompanionDiagnosticsforMetabolicDiseases 3.3 Novel trendsandtechnologiesincompaniondiagnosticsassaydevelopment 3.4 Companiondiagnosticsasa newtrendinpersonalizedmedicine 3.5 Biomarkersmarketasbasisforthe companiondiagnosticsindustry 3.6 KeyFindings 3.6.1 Top FactorsImpactingThe CompanionDiagnosticMarket 3.6.2 Top WinningStrategies 3.7 Porter’sfive forcesanalysis 3.7.1 Highswitchingcostleadstohigherbargainingpowerof suppliers 3.7.2 Highlydifferentiatedproductsleadstolowerbargainingpowerof buyers 3.7.3 Specificityof diagnosticslowersthe threatof substitutes 3.7.4 Highercapital investmentleadstolesserthreatof entrants 3.7.5 Fewcompetitorsleads tolowcompetitionamongplayers 3.8 GovernmentRegulations 3.8.1 FDA regulations 3.8.2 Europe 3.8.3 Japan 3.8.4 China 3.9 Value ChainAnalysis 3.10 Case Study 3.11 Drivers 3.11.1 Increasedpopularityof Personalizedmedicine 3.11.2 Increasingcasesof adverse drugreactions(ADRs) 3.11.3 Increase inthe Discoveryof Biomarkersasdrug targets. 3.11.4 Risingsuccessof co-developmentdrugsspeedilyapprovedbythe FDA 3.11.5 Technological advancements 3.11.6 Risingincidencesof diseases 3.12 Restraints 3.12.1 High Costinresearchand developmentof drugs
  6. 6. 3.12.1.1 Economicand scientificobstacles 3.12.2 Opportunities 3.12.2.1 Opportunitiesintreatmentof neurodegenerative diseases 3.12.2.2 Companiondiagnosticsforhereditarymutations CHAPTER 4. GLOBAL COMPANION DIAGNOSTIC MARKETBY INDICATIONS 4.1 Oncology 4.1.1 Companiondiagnosticsoncologymarketbygeography, 4.1.2 BreastCancer 4.1.2.1 companiondiagnosticsbreastcancermarketbygeography 4.1.3 LungCancer 4.1.3.1 companiondiagnosticslungcancermarketbygeography 4.1.4 Colorectal Cancer 4.1.4.1 companiondiagnosticsColorectal Cancermarketbygeography 4.1.5 Gastric cancer 4.1.5.1 companiondiagnosticsGastricCancermarketby geography 4.1.6 Melanomas 4.1.6.1 companiondiagnosticsMelanomamarketbygeography 4.2 InflammationandAutoimmune diseases 4.2.1 Companiondiagnosticsinflammationmarketbygeography 4.3 Companiondiagnosticsincardiovasculardiseases 4.3.1 Companiondiagnosticstestsforwarfarin 4.3.2 Companiondiagnosticscardiovascularmarketbygeography 4.4 CompaniondiagnosticsinCNSdisorders 4.4.1 CompaniondiagnosticsCNSmarketbygeography 4.5 Companiondiagnosticstestsinvirologydiseases 4.5.1 Companiondiagnosticsvirologymarketbygeography 4.6 Others 4.6.1 Companiondiagnosticsothersmarketbygeography CHAPTER 5. GLOBAL COMPANION DIAGNOSTIC MARKETBY TECHNOLOGY 5.1 Companiondiagnosticstechnologymarketbygeography 5.2 Immunohistochemistry 5.2.1 CompaniondiagnosticsImmmunohistochemistrymarketbygeography 5.3 MolecularDiagnostics 5.3.1 Companiondiagnosticsmoleculardiagnosticsmarketbytypes 5.3.2 CompaniondiagnosticsMolecularDiagnosticsmarketbygeography 5.3.3 In-situHybridization 5.3.3.1 FluorescentIn-situHybridization(FISH) 5.3.3.2 CISH(ChromogenicIn-SituHybridization) 5.3.3.3 CompaniondiagnosticsInsituHybridizationmarketbygeography 5.3.4 Real Time PCR 5.3.4.1 CompaniondiagnosticsRTPCRmarketby geography 5.3.5 Gene Sequencing 5.3.5.1 CompaniondiagnosticsSequencingmarketbygeography
  7. 7. 5.3.6 Others 5.3.6.1 Othersmolecularcompaniondiagnosticsmarketbygeography CHAPTER 6. GLOBAL COMPANION DIAGNOSTICS BY GEOGRAPHY 6.1 NorthAmerica 6.1.1 CompaniondiagnosticsNorthAmericamarketbyindication 6.2 Europe 6.2.1 CompaniondiagnosticsEurope marketbyindication 6.3 AsiaPacific 6.3.1 CompaniondiagnosticsAsiaPacificmarketbyindication 6.4 RoW 6.4.1 CompaniondiagnosticsRoWmarketbyindication CHAPTER 7. COMPANY PROFILES 7.1 Qiagen 7.1.1 CompanyOverview: 7.1.2 CompanySnapshot 7.1.3 BusinessPerformance 7.1.4 Strategymove anddevelopment 7.1.4.1 Principal strategiesCollaborations 7.1.4.2 SecondaryStrategiesApproval 7.1.5 SWOT Analysisof Qiagen 7.2 Dako(AgilentTechnologies) 7.2.1 CompanyOverview 7.2.2 CompanySnapshot 7.2.3 BusinessPerformance 7.2.4 StrategicMovesandDevelopment 7.2.4.1 Principal strategiesCollaboration 7.2.4.2 SecondaryStrategiesApproval 7.2.5 SWOT Analysisof Dako 7.3 Roche 7.3.1 Companyoverview 7.3.2 CompanySnapshot 7.3.3 BusinessPerformance 7.3.4 Strategiesmove anddevelopment 7.3.5 SWOT analysisof Roche 7.4 AbbottLaboratories,Inc. 7.4.1 CompanyOverview 7.4.2 CompanySnapshot 7.4.3 BusinessPerformance 7.4.4 Principal StrategiesCollaboration 7.4.5 SWOT Analysisof Abbot 7.5 BioMerieux 7.5.1 CompanyOverview 7.5.2 Companysnapshot: 7.5.3 BusinessPerformance
  8. 8. 7.5.4 StrategiesanddevelopmentApproval 7.5.5 SWOT Analysisof BioMerieux, 7.6 VentanaMedical Systems 7.6.1 CompanyProfile 7.6.2 CompanySnapshot 7.6.3 BusinessPerformance 7.6.4 Strategiesanddevelopment 7.6.5 SWOT Analysisof Ventana 7.7 MyriadGenetics,Inc. 7.7.1 CompanyOverview 7.7.2 Companysnapshot 7.7.3 BusinessPerformance 7.7.4 Strategies and development 7.7.5 SWOT Analysisof Myraid 7.8 Resonance HealthLtd 7.8.1 CompanyOverview 7.8.2 CompanySnapshot 7.8.3 Strategiesmove anddevelopment 7.8.4 SWOT Analysisof Ferriscan 7.9 LeicaMicrosystems 7.9.1 Companyoverview 7.9.2 CompanySnapshot 7.9.3 Strategiesmove andDevelopment 7.9.4 SWOT Analysisof LeicaMicrosystems 7.10 Life Technologies 7.10.1 CompanyOverview 7.10.2 CompanySnapshot 7.10.3 Businessperformance 7.10.4 Strategiesmove andDevelopment 7.10.5 SWOT Analysisof Life Technologies LIST OF TABLES TABLE 1 GLOBAL COMPANION DIAGNOSTICSMARKETBY INDICATION,2013-2020 ($MILLION) TABLE 2 COMPANION DIAGNOSTICSINDICATION MARKETBYGEOGRAPHY, 2013-2020 ($MILLION) TABLE 3 GLOBAL COMPANION DIAGNOSTICSMARKETBY ONCOLOGY,2013-2020, ($MILLION) TABLE 4 COMPANION DIAGNOSTICSONCOLOGYMARKETBY GEOGRAPHY, 2013-2020, ($MILLION) TABLE 5 COMPANION DIAGNOSTICSBREASTCANCERMARKETBY GEOGRAPHY,2013-2020 ($MILLION) TABLE 6 COMPANION DIAGNOSTICSLUNGCANCERMARKET BY GEOGRAPHY, 2013-2020 ($MILLION) TABLE 7 COMPANION DIAGNOSTICSCOLORECTALCANCERMARKETBY GEOGRAPHY, 2013-2020 ($MILLION) TABLE 8 COMPANION DIAGNOSTICSGASTRICCANCERMARKETBY GEOGRAPHY, 2013-2020 ($MILLION) TABLE 9 COMPANION DIAGNOSTICSMELANOMA MARKETBY GEOGRAPHY,2013-2020 ($MILLION) TABLE 10 COMPANION DIAGNOSTICSINFLAMMATION MARKETBY GEOGRAPHY,2013-2020 ($MILLION) TABLE 11 COMPANION DIAGNOSTICSCARDIOVASCULARMARKETBY GEOGRAPHY, 2013-2020 ($MILLION)
  9. 9. TABLE 12 COMPANION DIAGNOSTICSCNSMARKETBY GEOGRAPHY, 2013-2020 ($MILLION) TABLE 13 COMPANION DIAGNOSTICSVIROLOGYMARKETBY GEOGRAPHY, 2013-2020 ($MILLION) TABLE 14 COMPANION DIAGNOSTICSOTHERSMARKET BY GEOGRAPHY, 2013-2020 ($MILLION) TABLE 15 COMPANION DIAGNOSTICSTECHNOLOGYMARKET BY TECHNOLOGY 2013-2020 ($MILLION) TABLE 16 COMPANION DIAGNOSTICSTECHNOLOGYMARKET BY GEOGRAPHY, 2013-2020 ($MILLION) TABLE 17 COMPANION DIAGNOSTICSIMMMUNOHISTOCHEMISTRY MARKET BY GEOGRAPHY, 2013-2020 ($MILLION) TABLE 18 COMPANION DIAGNOSTICSMOLECULARDIAGNOSTICSMARKET BY TYPES 2013-2020 ($MILLION) TABLE 19 COMPANION DIAGNOSTICSMOLECULARDIAGNOSTICSMARKET BY GEOGRAPHY, 2013-2020 ($MILLION) TABLE 20 COMPANION DIAGNOSTICSIN SITUHYBRIDIZATION MARKET BY GEOGRAPHY, 2013-2020 ($MILLION) TABLE 21 COMPANION DIAGNOSTICSRTPCR MARKET BY GEOGRAPHY, 2013-2020 ($MILLION) TABLE 22 COMPANION DIAGNOSTICSSEQUENCINGMARKETBY GEOGRAPHY,2013-2020 ($MILLION) TABLE 23 OTHERS MOLECULAR COMPANION DIAGNOSTICSMARKETBY GEOGRAPHY, 2013-2020 ($MILLION) TABLE 24 COMPANION DIAGNOSTICSOTHERSMARKET BY GEOGRAPHY, 2013-2020 ($MILLION) TABLE 25 COMPANION DIAGNOSTICSNORTHAMERICA MARKET, 2013-2020 ($MILLION) TABLE 26 COMPANION DIAGNOSTICSEUROPEMARKET, 2013-2020 ($MILLION) TABLE 27 COMPANION DIAGNOSTICSASIA-PACIFICMARKET,2013-2020 ($MILLION) TABLE 28 COMPANION DIAGNOSTICSROWMARKET,2013-2020 ($MILLION) TABLE 29 QIAGEN SNAPSHOT TABLE 30 DAKO COMPANYSNAPSHOT TABLE 31 ROCHE COMPANYSNAPSHOT TABLE 32 ABBOTT COMPANYSNAPSHOT TABLE 33 BIOMERIEUX COMPANYSNAPSHOT TABLE 34 VENTANA COMPANYSNAPSHOT TABLE 35 MYRIAD COMPANYSNAPSHOT TABLE 36 RESONANCECOMPANYSNAPSHOT TABLE 37 LEICA COMPANYSNAPSHOT TABLE 38 LIFE TECHNOLOGIESCOMPANYSNAPSHOT LIST OF FIGURES FIG.1 COMPANION DIAGNOSTICSASA NEWTREND IN PERSONALIZEDMEDICINE FIG.2 EFFECTIVENESSOFCOMPANION DIAGNOSTICSIN LUNGCANCERPATIENTS FIG.3 LIST BIOMARKERSAND THE COMPANION DIAGNOSTICSFORVARIOUSDISEASES FIG.4 TOP FACTORSIMPACTINGTHE COMPANION DIAGNOSTICMARKET FIG.5 TOP WINNINGSTRATEGIES FIG.6 VALUE CHAIN ANALYSIS FIG.7 FINANCIALREVENUESBY BUSINESSUNITS (2013) FIG.8 FINANCIALREVENUESBY GEOGRAPHY(2013) FIG.9 SWOT ANALYSISOFQIAGEN FIG.10 FINANCIALREVENUEOF DAKO,BY SEGMENT (2012) FIG.11 SWOT ANALYSISOFDAKO FIG.12 FINANCIALREVENUEOF DAKO,BY SEGMENT
  10. 10. FIG.13 FINANCIALREVENUEOF DAKO,BY GEOGRAPHY FIG.14 SWOT ANALYSISOFROCHE FIG.15 REVENUE BY BUSINESSSEGMENTS FIG.16 REVENUE BY GEOGRAPHY FIG.17 SWOT ANALYSISOFABBOTT FIG.18 FINANCIALREVENUESBY GEOGRAPHY FIG.19 FINANCIALREVENUESBY TECHNOLOGY FIG.20 SWOT ANALYSISOFBIOMERIEUX FIG.21 SWOT ANALYSISOFVENTANA FIG.22 REVENUE BY DIAGNOSTICTYPE FIG.23 SWOT ANALYSISOFMYRAID FIG.24 SWOT ANALYSISOFFERRISCAN FIG.25 SWOT ANALYSISOFLEICA MICROSYSTEMS FIG.26 REVENUE BY END MARKETS FIG.27 SWOT ANALYSISOFLIFE TECHNOLOGIES Contact Us: Sona Padman 5320 SW MacadamAvenue, Suite 100, Portland, OR97239 United States Direct: +1 (617) 674-4143 Toll Free: +1 (855) 711-1555 (U.S. & Canada) Fax: +1 (855) 550-5975 Email: sales@reportsandintelligence.com Web: http://www.reportsandintelligence.com/

×